Scientific publications

Immune-dependent antineopastic effects of cisplatin plus pyridoxine in Non-Small Cell Lung Cancer

Jun 4, 2015 | Magazine: Oncogene

F Aranda 1, N Bloy 2, J Pesquet 1, B Petit 3, K Chaba 4, A Sauvat 1, O Kepp 1, N Khadra 1, D Enot 1, C Pfirschke 5, M Pittet 5, L Zitvogel 6, G Kroemer 7, L Senovilla 8


cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects.

However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.

CITA DEL ARTÍCULO Oncogene. 2015 Jun 4;34(23):3053-62. doi: 10.1038/onc.2014.234. Epub 2014 Jul 28.